Cost-effectiveness of direct non-vitamin K oral anticoagulants versus vitamin K antagonists for the management of patients with non-valvular atrial fibrillation based on …
V Lorenzoni, S Pirri, G Turchetti - Clinical drug investigation, 2021 - Springer
Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …
Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
O Königsbrügge, A Simon, H Domanovits… - BMC cardiovascular …, 2016 - Springer
Background The clinical practice of stroke prevention in atrial fibrillation (AF) with direct oral
anticoagulants (DOACS) differs from anticoagulation in randomized trial patients. We …
anticoagulants (DOACS) differs from anticoagulation in randomized trial patients. We …
Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world'atrial fibrillation patients: a comparison …
MA Esteve-Pastor, JM Rivera-Caravaca… - International journal of …, 2018 - Elsevier
Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as
an alternative to vitamin K antagonists (VKA) for atrial fibrillation (AF) patients. Some studies …
an alternative to vitamin K antagonists (VKA) for atrial fibrillation (AF) patients. Some studies …
Estimated effectiveness and safety of nonvitamin K antagonist oral anticoagulants compared with optimally acenocoumarol anticoagulated “real-world” in patients with …
MA Esteve-Pastor, JM Rivera-Caravaca… - The American Journal of …, 2018 - Elsevier
Nonvitamin K antagonist oral anticoagulants (NOACs) have been proposed as an
alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative …
alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative …
Outcome reporting from clinical trials of non-valvular atrial fibrillation treated with traditional Chinese medicine or Western medicine: a systematic review
R Qiu, J Hu, Y Huang, S Han, C Zhong, M Li, T He… - BMJ open, 2019 - bmjopen.bmj.com
Objectives To examine variation in outcomes, outcome measurement instruments (OMIs)
and measurement times in clinical trials of non-valvular atrial fibrillation (NVAF) and to …
and measurement times in clinical trials of non-valvular atrial fibrillation (NVAF) and to …
Pharmacological and non-pharmacological treatments for stroke prevention in patients with atrial fibrillation
L Ueberham, N Dagres, TS Potpara, A Bollmann… - Advances in …, 2017 - Springer
Atrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic
events, which can be effectively prevented using oral anticoagulation (OAC) with either …
events, which can be effectively prevented using oral anticoagulation (OAC) with either …
[HTML][HTML] The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study
Objective We aimed to describe sociodemographic, comorbidities, co-medication and risk of
thromboembolic events and bleeding in patients with NVAF initiating oral anticoagulants …
thromboembolic events and bleeding in patients with NVAF initiating oral anticoagulants …
Direct oral anticoagulants versus vitamin K antagonists in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis
Background Clinical guidelines recommend peri-cardioversion anticoagulation in patients
with atrial fibrillation (AF). We performed a systematic review and meta-analysis to compare …
with atrial fibrillation (AF). We performed a systematic review and meta-analysis to compare …
Comparing non-vitamin K antagonist oral anticoagulants (NOACs) to different Coumadins: the Win-Win scenarios
TS Potpara - Thrombosis and haemostasis, 2018 - thieme-connect.com
In addition to warfarin, the family of vitamin K antagonist (VKA) oral anticoagulants includes
acenocoumarol, phenprocoumon, phenindione and fluindione. 1 These drugs alter the …
acenocoumarol, phenprocoumon, phenindione and fluindione. 1 These drugs alter the …
Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score
M Giner-Soriano, M Casajuana, A Roso-Llorach… - Atencion …, 2019 - europepmc.org
Objetivo: El objetivo de este estudio es analizar el uso, la efectividad, la seguridad y los
costes de la prevención de ictus en fibrilación auricular (FA) no valvular en pacientes que …
costes de la prevención de ictus en fibrilación auricular (FA) no valvular en pacientes que …